keyword
MENU ▼
Read by QxMD icon Read
search

BRVO

keyword
https://www.readbyqxmd.com/read/29705175/ischemic-retinal-vein-occlusion-characterizing-the-more-severe-spectrum-of-retinal-vein-occlusion
#1
REVIEW
Meiaad Khayat, Michael Williams, Noemi Lois
Retinal vein occlusion (RVO), including central (CRVO), branch (BRVO) and hemicentral and hemispheric RVO, is the second most common vascular cause of visual loss, surpassed only by diabetic retinopathy. The presence and extent of retinal ischemia in RVO is associated with a worse prognosis. On this basis, most previously conducted studies considered iRVO and non-iRVO as separate entities based on set thresholds of existing retinal ischemia, as determined by fundus fluorescein angiography (FFA). Other diagnostic technologies have been used specifically in the differentiation of iCRVO and non-iCRVO...
April 26, 2018: Survey of Ophthalmology
https://www.readbyqxmd.com/read/29600177/intravitreal-anti-vegf-agents-oral-glucocorticoids-and-laser-photocoagulation-combination-therapy-for-macular-edema-secondary-to-retinal-vein-occlusion-preliminary-report
#2
Xiao-Xiao Feng, Cheng Li, Wan-Wen Shao, Yong-Guang Yuan, Xiao-Bing Qian, Qi-Shan Zheng, Yu-Jie Li, Qian-Ying Gao
AIM: To evaluate the efficacy and safety of combined anti-vascular endothelial growth factor (VEGF) agents, oral glucocorticoid, and laser photocoagulation therapy for macular edema (ME) secondary to retinal vein occlusion (RVO). METHODS: This study included 16 eyes of 16 patients with RVO-associated ME. Patients were initially treated with oral prednisone and an intravitreal anti-VEGF agent. Two weeks later, patients underwent standard laser photocoagulation. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and retinal vessel oxygenation were examined over 12mo...
2018: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/29572577/mechanisms-of-vision-loss-in-eyes-with-macular-edema-associated-with-retinal-vein-occlusion
#3
REVIEW
Hiroyuki Iijima
Anti-vascular endothelial growth factor agents reduce macular edema and improve vision in eyes with macular edema associated with retinal vein occlusion (RVO), including branch RVO (BRVO) and central RVO. However, not all eyes with resolved macular edema show satisfactory best corrected visual acuity. Photoreceptor impairment can mostly explain the vision loss in these cases. Photoreceptor damage can be caused by subretinal hemorrhage in the central fovea and hard exudates or their precursor derived from concentrated lipoproteins originating from leaky retinal vessel extravasation...
March 23, 2018: Japanese Journal of Ophthalmology
https://www.readbyqxmd.com/read/29567791/baseline-choroidal-thickness-as-a-short-term-predictor-of-visual-acuity-improvement-following-antivascular-endothelial-growth-factor-therapy-in-branch-retinal-vein-occlusion
#4
Nadim Rayess, Ehsan Rahimy, Gui-Shuang Ying, Maria Pefkianaki, Jason Franklin, Carl D Regillo, Allen C Ho, Jason Hsu
PURPOSE: To evaluate the association between subfoveal choroidal thickness (SFCT) and branch retinal vein occlusion (BRVO) eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy. METHODS: Retrospective cohort study of treatment naïve BRVO eyes treated with 3 monthly anti-VEGF injections. All patients received enhanced depth imaging spectral-domain optical coherence tomography scans to determine SFCT and central macular thickness (CMT). Baseline predictors (particularly SFCT) for functional response (best-corrected visual acuity (BCVA) gain ≥2 lines) were assessed at 3 months using univariate and multivariate analyses...
March 22, 2018: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29566387/spectral-domain-optical-coherence-tomography-driven-treat-and-extend-and-pro-re-nata-regimen-in-patients-with-macular-oedema-due-to-retinal-vein-occlusion-24-month-evaluation-and-outcome-predictors
#5
Maria-Magdalena Guichard, Anton R Xavier, Cengiz Türksever, Christian Pruente, Katja Hatz
PURPOSE: To analyse the efficacy and outcome predictors of ranibizumab using a spectral-domain optical coherence tomography (SD-OCT)-driven treat-and-extend regimen (TER) versus SD-OCT-driven pro re nata regimen (PRN) in patients with cystoid macular oedema (CME) due to branch or central retinal vein occlusion (BRVO, CRVO). METHODS: Retrospective, consecutive case series. Evaluation included best corrected visual acuity (BCVA), morphological parameters on SD-OCT, and treatment frequency...
March 22, 2018: Ophthalmic Research
https://www.readbyqxmd.com/read/29545416/correlation-between-reduction-in-macular-vessel-density-and-frequency-of-intravitreal-ranibizumab-for-macular-oedema-in-eyes-with-branch-retinal-vein-occlusion
#6
Taiji Hasegawa, Sakura Murakawa, Ichiro Maruko, Akiko Kogure-Katakura, Tomohiro Iida
AIM: To determine whether there is a significant correlation between the reduction in macular vessel density and the recurrence of macular oedema in eyes with branch retinal vein occlusion (BRVO). METHODS: We reviewed the medical records of 27 eyes with macular oedema associated with BRVO. All eyes had received pro re nata intravitreal ranibizumab (IVR) injection. A reinjection of ranibizumab was performed when the central foveal thickness was ≥300 µm. At 12 months, patients without additional IVR for the last 4 months were placed in the resolved group, otherwise they were placed in the recurrence group...
March 15, 2018: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29511062/neuroretinal-atrophy-following-resolution-of-macular-oedema-in-retinal-vein-occlusion
#7
Dominika Podkowinski, Ana-Maria Philip, Wolf-Dieter Vogl, Jutta Gamper, Hrvoje Bogunovic, Bianca S Gerendas, Bilal Haj Najeeb, Sebastian M Waldstein, Ursula Schmidt-Erfurth
BACKGROUND/AIMS: To characterise neuroretinal atrophy in retinal vein occlusion (RVO). METHODS: We included patients with central/branch RVO (CRVO=196, BRVO=107) who received ranibizumab according to a standardised protocol for 6 months. Retinal atrophy was defined as the presence of an area of retinal thickness (RT) <260 µm outside the foveal centre. Moreover, the thickness of three distinct retinal layer compartments was computed as follows: (1) retinal nerve fibre layer to ganglion cell layer, (2) inner plexiform layer (IPL) to outer nuclear layer (ONL) and (3) inner segment/outer segment junction to retinal pigment epithelium...
March 6, 2018: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29505751/dexamethasone-intravitreal-implant-downregulates-pdgfr-%C3%AE-and-upregulates-caveolin-1-in-experimental-branch-retinal-vein-occlusion
#8
Lasse Jørgensen Cehofski, Anders Kruse, Sigriður Olga Magnusdottir, Alexander Nørgård Alsing, Jonas Ellegaard Nielsen, Svend Kirkeby, Bent Honoré, Henrik Vorum
A dexamethasone (DEX) intravitreal implant (OZURDEX) provides an effective treatment of inflammation secondary to branch retinal vein occlusion (BRVO). Retinal proteome changes which mediate the beneficial effects of the implant remain poorly understood. To study retinal proteome changes in BRVO following an intervention with a DEX implant this study combined an experimental model of BRVO with proteomic techniques. In eight Danish Landrace pigs experimental BRVO was induced in both eyes using argon laser. After inducing BRVO a DEX implant was injected into the right eye of each animal while the left control eye was given an identical injection without an implant...
March 2, 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29463937/results-of-a-treat-and-eextend-regimen-of-intravitreal-ranibizumab-injection-for-macular-edema-due-to-branch-retinal-vein-occlusion
#9
Mika Hosogi, Yuki Morizane, Yusuke Shiode, Shinichiro Doi, Fumiaki Kumase, Shuhei Kimura, Mio Hosokawa, Masayuki Hirano, Shinji Toshima, Kosuke Takahashi, Atsushi Fujiwara, Fumio Shiraga
To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than 12 weeks (continued TAE group). Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and predictive factors for inclusion in the TAE to PRN group were analyzed...
February 2018: Acta Medica Okayama
https://www.readbyqxmd.com/read/29393235/impact-of-early-anatomical-and-functional-responses-to-bevacizumab-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#10
Donghyoun Noh, Gahyung Ryu, Junyeop Lee, Min Sagong
PURPOSE: To evaluate whether early anatomical and visual acuity (VA) responses to intravitreal bevacizumab (IVB) in macular edema secondary to branch retinal vein occlusion (BRVO) are associated with 1-year follow-up outcomes. METHODS: Ninety-nine treatment-naïve patients (99 eyes) with macular edema after BRVO treated with IVB were analyzed retrospectively. All patients received single injection and were followed up with pro re nata regimen for at least 12 months...
January 31, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29376223/bevacizumab-versus-dexamethasone-implant-followed-by-bevacizumab-for-the-treatment-of-macula-edema-associated-with-branch-retinal-vein-occlusion
#11
Su Young Moon, Kwan Hyuk Cho, Se Joon Woo, Sung Pyo Park, Yong Kyu Kim
PURPOSE: To compare visual and anatomical outcomes of intravitreal injections of bevacizumab and dexamethasone implant (Ozurdex) treatment for macular edema associated with branch retinal vein occlusion (BRVO). METHODS: We retrospectively reviewed patients who underwent intravitreal bevacizumab administered monthly on a pro re nata (PRN) basis (26 eyes, IVB group) or an initial 700-μg dexamethasone implant followed by a bevacizumab PRN injection (20 eyes, IVD group) for treatment of macular edema associated with BRVO...
February 2018: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/29366614/correlation-between-ischemic-index-of-retinal-vein-occlusion-and-oxygen-saturation-in-retinal-vessels
#12
Irena Šínová, Jiří Řehák, Jana Nekolová, Nad'a Jirásková, Petra Haluzová, Tereza Řeháková, Barbora Bábková, Libor Hejsek, Martin Šín
PURPOSE: To evaluate the relationship between the ischemic index and the oxygen saturation in retinal vessels in patients with retinal vein occlusion. DESIGN: Prospective, cross-sectional study. METHODS: We performed a prospective study. The cohort consisted of 43 eyes of 43 patients with retinal vein occlusions (RVO), 23 of whom had central retinal vein occlusions (CRVO) and 20 who had branch retinal vein occlusions (BRVO). We evaluated the retinal vessel saturation using an automatic retinal oximetry device...
April 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29339917/association-of-treatment-adherence-with-real-life-va-outcomes-in-amd-dme-and-brvo-patients
#13
Christoph Ehlken, Mandy Helms, Daniel Böhringer, Hansjürgen T Agostini, Andreas Stahl
Purpose: Real-life clinical outcomes of patients treated with anti-VEGF drugs for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or macular edema secondary to branch retinal vein occlusion (BRVO) are often inferior to results from randomized clinical trials. This observational cohort study investigates treatment adherence and real-life clinical outcomes within the first year of treatment. Patients and methods: A total of 708 treatment-naïve patients (466 nAMD, 134 DME, and 108 BRVO) were included...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29274022/outcome-of-treat-and-monitor-regimen-of-aflibercept-and-ranibizumab-in-macular-edema-secondary-to-non-ischemic-branch-retinal-vein-occlusion
#14
Francesco Pichi, Ahmed Mohammed Elbarky, Tarek Roshdy Elhamaky
PURPOSE: To compare the efficacy of a modified PRN treatment regimen ("treat and monitor") of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. METHODS: Seventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a "treat and monitor" treatment regimen with monthly follow-up for 12 months...
December 22, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/29225460/intravitreal-bevacizumab-injections-versus-dexamethasone-implant-for-treatment-na%C3%A3-ve-retinal-vein-occlusion-related-macular-edema
#15
Ilkka Laine, Juha-Matti Lindholm, Petteri Ylinen, Raimo Tuuminen
Purpose: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO). Design: A retrospective single-center study. Subjects: A total of 135 eyes of 135 patients with BRVO (n=83) and CRVO (n=52). Methods: Changes in clinical parameters were recorded before treatment and at the first and third month after commencement of IVB (n=121) and DEX (n=14)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29222552/animal-models-of-retinal-vein-occlusion
#16
REVIEW
Meiaad Khayat, Noemi Lois, Michael Williams, Alan W Stitt
Purpose: To provide a comprehensive and current review on the available experimental animal models of retinal vein occlusion (RVO) and to identify their strengths and limitations with the purpose of helping researchers to plan preclinical studies on RVO. Methods: A systematic review of the literature on experimental animal models of RVO was undertaken. Medline, SCOPUS, and Web of Science databases were searched. Studies published between January 1, 1965, and March 31, 2017, and that met the inclusion criteria were reviewed...
December 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29190240/comparing-microperimetric-and-structural-findings-in-patients-with-branch-retinal-vein-occlusion-and-diabetic-macular-edema
#17
Amun Sachdev, Magdalena Edington, Rupal Morjaria, Victor Chong
PURPOSE: To compare retinal sensitivity and central retinal thickness in patients with focal diabetic macular edema (DME) and edema secondary to branch retinal vein occlusion (BRVO). METHODS: In this consecutive, cross-sectional, observational study, patients with either DME or BRVO underwent measurements for best-corrected visual acuity, microperimetry, and spectral domain optical coherence tomography. Retinal thickness and sensitivity were measured using Optos Spectral optical coherence tomography/scanning laser ophthalmoscopy (Optos plc, Dunfermline, Scotland, United Kingdom)...
November 22, 2017: Retina
https://www.readbyqxmd.com/read/29185099/real-life-clinical-data-for-dexamethasone-and-ranibizumab-in-the-treatment-of-branch-or-central-retinal-vein-occlusion-over-a-period-of-six-months
#18
Sibylle Winterhalter, Annabelle Eckert, Gerrit-Alexander Vom Brocke, Alice Schneider, Dominika Pohlmann, Daniel Pilger, Antonia M Joussen, Matus Rehak, Ulrike Grittner
PURPOSE: To evaluate the therapeutic outcome for dexamethasone implant (DEX) or intravitreal ranibizumab (IVR) injections over 6 months in patients with macular edema due to branch or central retinal vein occlusion (BRVO, CRVO), in a real-life setting. METHODS: A total of 107 patients with BRVO or CRVO were included into this retrospective single-center observational study. Patients were treated with monotherapy consisting of DEX or three monthly IVR injections following a pro re nata regimen (PRN)...
February 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29099501/efficacy-and-timing-of-adjunctive-therapy-in-the-anti-vegf-treatment-regimen-for-macular-oedema-in-retinal-vein-occlusion-12-month-real-world-result
#19
P L Lip, P Cikatricis, A Sarmad, E M Damato, R Chavan, A Mitra, S Elsherbiny, Y Yang, B Mushtaq
PurposeVarious combination treatment regimens have been tried to improve the short-term efficacy of intravitreal monotherapy for the treatment of macular oedema (MO) secondary to retinal vein occlusion (RVO). Our study introduces the RandOL protocol (Ranibizumab and Ozurdex with Laser photocoagulation) of initial anti-VEGF therapy, controlling recurrent non-ischaemic MO with an intravitreal steroid and applying laser therapy to non-perfused retina. We describe our 12-month follow-up experience on timing for adjunctive therapy and real-world effectiveness and safety data...
March 2018: Eye
https://www.readbyqxmd.com/read/29094327/reduced-light-sensitivity-due-to-impaired-retinal-perfusion-in-branch-retinal-vein-occlusion
#20
Hiroyuki Iijima
PURPOSE: To study the reduction in light sensitivity in areas where impaired retinal perfusion was established by fluorescein angiogram (FA) in eyes with branch retinal vein occlusion (BRVO) that recovered from retinal edema and hemorrhage. DESIGN: Retrospective observational case series. METHODS: A study of the reduction in light sensitivity demonstrated by total deviation display of the Humphrey perimetry program 30-2 in 43 eyes from 42 patients with BRVO, whose perfusion status was assessed by FA images taken at least 6 months after disease onset...
March 2018: Japanese Journal of Ophthalmology
keyword
keyword
44182
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"